- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer
First of Nine Studies, Examining the Ability of Rivaroxaban to Reduce the Burden of Cancer-Associated Blood Clots, Presented at ASH Annual Meeting
Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis
XALIA is First Prospective Study to Confirm Benefit of a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) for Treating Deep Vein Thrombosis in Routine Clinical Practice, Adds to More than 91,000 Patients Enrolled in Real-World Studies
DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent
Largest Schizophrenia and Schizoaffective Disorder Caregiver Survey Reveals Overwhelming Burden and Inadequate Assistance
Findings Highlight Need for Education and More Support for Caregivers
Janssen Announces Global License and Development Rights Agreement with Hanmi Pharmaceutical for Novel Clinical Stage Biologic to Treat Diabetes and Obesity
Novel Oxyntomodulin-Based Therapy Bolsters Janssen’s Metabolism Portfolio
First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced
Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma
Approval based on largest Phase 3 study conducted to date in this patient population